1. "Sean Devlin"
  2. "Eric Smith"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (4)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (19)
  2. Center for Hematologic Malignancies (19)
  3. Department of Medicine (19)
  4. Epidemiology and Biostatistics (19)
  5. Hematologic Malignancies Research (19)
  6. Hematologic Malignancies, Division of (19)

More Groups

People
  1. Eric Smith (19)
  2. Sean Devlin (19)
  3. Alexander Lesokhin (17)
  4. Carl Landgren (17)
  5. Sergio Giralt (17)
  6. Sham Mailankody (17)

More People

Years
  1. 2021 (2)
  2. 2020 (3)
  3. 2019 (5)
  4. 2018 (4)
  5. 2017 (3)
  6. 2016 (1)

More Years

Publications
  1. Blood (10)
  2. Biology of Blood and Marrow Transplantation (3)
  3. Journal of Clinical Oncology (2)
  4. American Journal of Hematology (1)
  5. Blood Advances (1)
  6. Clinical Lymphoma, Myeloma and Leukemia (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Elsevier Inc. (4)
  3. American Society of Clinical Oncology (2)
  4. John Wiley & Sons, Inc. (1)
  5. Taylor & Francis Group (1)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
    Journal Article

    Jain, T.; Knezevic, A.; Pennisi, M.; Chen, Y.; Ruiz, J. D.; Purdon, T. J.; Devlin, S. M.; Smith, M.; Shah, G. L.; Halton, E.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma
    Journal Article

    Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Meeting Abstract

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Korde, N.; Lendvai, N.; Hassoun, H.; Lesokhin, A. M.; Lahoud, O. B.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save